GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immunitybio IBRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

7.11

-17.71%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Immunitybio

From its filings with the US Securities and Exchange Commission

SEC filings

Immunitybio is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IBRX. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $113.3m and a net loss of $351.4m. At that date it held total assets of $501.9m and shareholders' equity of −$500.5m. By region, U.S. accounted for 99.8%, followed by Europe at 0.2%.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Jul 2015
Employees
691
Head office
3530 JOHN HOPKINS COURT, SAN DIEGO, CA, 92121
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Large accelerated filer

Leadership

Pay as last reported

  • Dr. Patrick Soon-ShiongExecutive Chairman of the Board, Global Chief Scientific and Medical Officer, since 2015$8.2m
  • Mr. Richard AdcockPresident, Chief Executive Officer, Director, since 2020$11.0m
  • Mr. David SachsChief Financial Officer$3.4m
  • Dr. Barry SimonChief Corporate Affairs, Director, since 2007$659,661
  • Ms. Cheryl CohenLead Independent Director$512,500
  • Mr. Michael BlaszykIndependent Director$510,000
  • Gen. (Retd.) Wesley ClarkIndependent Director$465,000
  • Dr. Linda MaxwellIndependent Director$487,500
  • Ms. Christobel SeleckyIndependent Director$470,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
42
Environment
39
Social
53
Governance
36
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Immunitybio Inc. possesses several strengths that contribute to its competitive advantage:

Weaknesses

  • Despite its strengths, Immunitybio Inc. faces certain weaknesses:

Opportunities

  • Immunitybio Inc. can leverage the following opportunities to further its growth:

Threats

  • Immunitybio Inc. faces various threats that could negatively impact its performance:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.